BR0211488A - Formas cristalinas vi e vii de atorvastina cálcica - Google Patents

Formas cristalinas vi e vii de atorvastina cálcica

Info

Publication number
BR0211488A
BR0211488A BR0211488-7A BR0211488A BR0211488A BR 0211488 A BR0211488 A BR 0211488A BR 0211488 A BR0211488 A BR 0211488A BR 0211488 A BR0211488 A BR 0211488A
Authority
BR
Brazil
Prior art keywords
calcium
atorvastin
vii
crystalline forms
forms
Prior art date
Application number
BR0211488-7A
Other languages
English (en)
Portuguese (pt)
Inventor
M Satyanarayana Reddy
Chakilam Nagaraju
Gudipati Srinivasulu
Katakam Sinivas
Sagyam Rajeswar Reddy
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of BR0211488A publication Critical patent/BR0211488A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0211488-7A 2001-07-30 2002-01-07 Formas cristalinas vi e vii de atorvastina cálcica BR0211488A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN620MA2001 2001-07-30
PCT/US2002/000431 WO2003011826A1 (en) 2001-07-30 2002-01-07 Crystalline forms vi and vii of atorvastatin calcium

Publications (1)

Publication Number Publication Date
BR0211488A true BR0211488A (pt) 2004-08-17

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211488-7A BR0211488A (pt) 2001-07-30 2002-01-07 Formas cristalinas vi e vii de atorvastina cálcica

Country Status (19)

Country Link
EP (2) EP1414796A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005500351A (cg-RX-API-DMAC7.html)
KR (1) KR20040019043A (cg-RX-API-DMAC7.html)
CN (1) CN100471836C (cg-RX-API-DMAC7.html)
AU (1) AU2002255479B2 (cg-RX-API-DMAC7.html)
BG (1) BG108518A (cg-RX-API-DMAC7.html)
BR (1) BR0211488A (cg-RX-API-DMAC7.html)
CA (1) CA2454500C (cg-RX-API-DMAC7.html)
CZ (1) CZ2004126A3 (cg-RX-API-DMAC7.html)
EE (1) EE200400048A (cg-RX-API-DMAC7.html)
HR (1) HRP20040077A2 (cg-RX-API-DMAC7.html)
IL (2) IL159626A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000889A (cg-RX-API-DMAC7.html)
NO (1) NO20040390L (cg-RX-API-DMAC7.html)
NZ (1) NZ530785A (cg-RX-API-DMAC7.html)
PL (1) PL368647A1 (cg-RX-API-DMAC7.html)
RU (1) RU2304139C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003011826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200400573B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
PL372303A1 (en) * 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
JP4422488B2 (ja) 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
CA2560252C (en) 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
TW200825092A (en) 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
BR9609872A (pt) 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI1535613T1 (sl) * 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
HRP20030454A2 (en) * 2000-11-16 2005-10-31 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)

Also Published As

Publication number Publication date
CA2454500C (en) 2009-11-10
HRP20040077A2 (en) 2004-06-30
EE200400048A (et) 2004-04-15
RU2004103470A (ru) 2005-06-20
NO20040390L (no) 2004-01-29
EP1414796A1 (en) 2004-05-06
KR20040019043A (ko) 2004-03-04
NZ530785A (en) 2005-10-28
CN1537098A (zh) 2004-10-13
JP2005500351A (ja) 2005-01-06
WO2003011826A1 (en) 2003-02-13
RU2304139C2 (ru) 2007-08-10
CA2454500A1 (en) 2003-02-13
PL368647A1 (en) 2005-04-04
AU2002255479B2 (en) 2008-09-11
IL159626A0 (en) 2004-06-01
MXPA04000889A (es) 2004-06-03
CZ2004126A3 (cs) 2004-12-15
IL159626A (en) 2013-04-30
CN100471836C (zh) 2009-03-25
BG108518A (en) 2004-08-31
EP2292600A1 (en) 2011-03-09
ZA200400573B (en) 2005-05-11

Similar Documents

Publication Publication Date Title
MXPA04000889A (es) Formas cristalinas vi y vii de atorvastatina calcica.
PY0213405A (es) FORMAS CRISTALINAS DE LA SAL DE CALCIO DEL ACIDO [R-(R*,R*)]-2-(4- FLUOROFENIL)-B, o- DIHIDROXI-5-(1-METILETIL)-3-FENIL-4-[(FENILAMINO) CARBONIL]-1H-PIRROL-1-HEPTANOICO (2:1)
BG107856A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
PL1663989T3 (pl) Krystaliczna postać soli wapniowej kwasu bis[(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-metylo[(metylosulfonylo)-amino-pirymidyn-5-ylo](3R,5S)-3,5-dihydroksyhept-6-enowego]
ATE411980T1 (de) (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
WO2004084453A3 (en) METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
BR0115482A (pt) Composição de sacralose melhorada e processo para sua preparação
ECSP095220A (es) Derivados de n-fenil-2-pirimidin-amina
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
DE602004012746D1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-3-azabicycloä3,1,0ühexane-2-carboxamide,n-ä3-amino-1-(cyclobutylmethyl)-2,3-dioxopropylü ü-3-ä(2s)-2-äää1,1-dimethylethylüaminoücarbonylaminoü-3,3-dimethyl-1-oxobutylü-6,6-dimethyl
RU93004923A (ru) Усовершенствованный способ получения микробных пестицидов с покрытием и пестициды, полученные этим способом
BRPI0407145A (pt) Pirazolilcarboxanilidas para combater microorganismos indesejados
EP1423137A4 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
AU2001242473A1 (en) Active substance combinations having insecticidal and acaricidal properties
BRPI0510713A (pt) formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
BRPI0414107A (pt) produtos intermediários para a preparação de hìbridos de oxazolidinon-quinolona
EP2586427A3 (en) Balsalazide formulations and manufacture thereof
BR0212153A (pt) Compostos e respectivos processos de preparação e de isolamento de dicloreto de 2-difluormetilornitina
BRPI0414457A (pt) formas cristalinas do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-c arbonil]-1h-pirrol-1-heptanóico
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina
CA2486571A1 (en) Pharmaceutical composition
BR0112876A (pt) Processo para preparação de discodermolida e seus análogos
BR0314757A (pt) Pirrolinas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]